Target intelligence / Profile preview

Guanylate cyclase 2C (GUCY2C) (GUCY2C)

Target
GUCY2C
Molecular classification
Receptor, Enzyme, Transmembrane protein
01

Overview

Guanylate cyclase 2C (GUCY2C), also known as the heat-stable enterotoxin receptor, is a transmembrane receptor primarily expressed on the apical surface of intestinal epithelial cells [1, 5]. Its extracellular domain serves as the binding site for endogenous ligands such as guanylin and uroguanylin, as well as bacterial heat-stable enterotoxins [1, 10]. Upon ligand binding to the extracellular domain, the intracellular catalytic domain is activated, converting GTP into cyclic GMP (cGMP) [7, 11]. This second messenger regulates fluid and electrolyte homeostasis by activating the cystic fibrosis transmembrane conductance regulator (CFTR) and inhibiting the sodium-hydrogen exchanger 3 (NHE3) [8, 12]. In clinical medicine, GUCY2C is a major therapeutic target for gastrointestinal disorders like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), where agonists like linaclotide and plecanatide are used to increase intestinal secretion and motility [10, 11]. Beyond its role in fluid balance, GUCY2C acts as a tumor suppressor in the intestine, and its expression is a highly specific biomarker for metastatic colorectal cancer [7, 16]. Novel therapies, including antibody-drug conjugates and CAR-T cells, are currently being developed to target the GUCY2C extracellular domain in oncology [14, 16].

Other names
Guanylyl cyclase CGC-CHeat-stable enterotoxin receptorhSTARIntestinal guanylate cyclaseSTARGUC2CGCC
02

Mechanism of action

Agonism of the extracellular domain activates the intracellular catalytic domain, increasing cyclic GMP (cGMP) levels, which regulates fluid secretion and cell homeostasis.

03

Biological functions

Signal transductionFluid and electrolyte homeostasisIntestinal motilityCell proliferationApoptosisIntestinal barrier integrity
04

Disease associations

Irritable bowel syndrome with constipationChronic idiopathic constipationColorectal cancerDiarrheaMeconium ileus
05

Safety considerations

DiarrheaDehydrationPotential for off-target effects in the CNS
06

Interacting drugs

Linaclotide

4 more in the full profile.

07

Biomarkers

GUCY2C expression in lymph nodesGUCY2C mRNA levels

Beyond the preview

Go deeper on Guanylate cyclase 2C (GUCY2C) (GUCY2C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guanylate cyclase 2C (GUCY2C) (GUCY2C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call